Literature DB >> 3030999

Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.

T B Sorg, M H Cynamon.   

Abstract

The in-vitro activity of a beta-lactamase inhibitor (clavulanic acid, sulbactam, BL-P2013 or BL-P2090) in combination with ampicillin against 13 isolates of Mycobacterium tuberculosis was determined by broth dilution. The agents were tested in 1:1 molar ratio of ampicillin to beta-lactamase inhibitor. The beta-lactamase inhibitors alone did not inhibit growth at the highest concentration tested. The MIC90 for ampicillin alone was greater than 32 mg/l. Clavulanic acid plus ampicillin was the most active combination with an MIC90 of 11 microM (4 mg/l of ampicillin). The MIC90 of ampicillin in combination with sulbactam, BL-P2013 or BL-P2090 was 23 microM (8 mg/l of ampicillin). A 1:1 ratio of ampicillin to inhibitor was more active than was a 2:1 ratio. The addition of a beta-lactamase inhibitor to ampicillin greatly improves its in-vitro activity against M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030999     DOI: 10.1093/jac/19.1.59

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis.

Authors:  Sanjib Bhakta; Joyoti Basu
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 5.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

6.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

Authors:  D Herbert; C N Paramasivan; P Venkatesan; G Kubendiran; R Prabhakar; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Unusual conformation of the SxN motif in the crystal structure of penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2010-03-03       Impact factor: 5.469

8.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  C Segura; M Salvadó; I Collado; J Chaves; A Coira
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 10.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.